Rein Therapeutics faces Nasdaq delisting notice after shares trade below $1 bid threshold

• Rein Therapeutics received a Nasdaq notice of delisting risk on Aug. 21, 2026 due to a sub-$1 bid price.
• Non-compliance cited under Nasdaq Listing Rule 5550(a)(1) following 30 consecutive trading days below $1.
• Deadline to regain compliance is Feb. 17, 2027 via at least $1 closing bid for 10 consecutive business days.
• Failure to cure could trigger suspension and delisting procedures; an additional compliance period is possible but not assured.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-371260), on August 27, 2026, and is solely responsible for the information contained therein.